| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Magdalena Tyczyńska, Marta Gędek, Adam Brachet, Wojciech Stręk, Jolanta Flieger, Grzegorz Teresiński, Jacek Ba. Trace Elements in Alzheimer's Disease and Dementia: The Current State of Knowledge. Journal of clinical medicine. vol 13. issue 8. 2024-04-27. PMID:38673657. |
parkinson's disease is caused by the accumulation of fe in the midbrain dopaminergic nucleus, and the pathogenesis of multiple sclerosis derives from zn deficiency, leading to an imbalance between t cell functions. |
2024-04-27 |
2024-04-29 |
Not clear |
| Jessica Marie Barbara, Adrian Pac. Amantadine toxicity causing visual hallucinations. Practical neurology. 2023-07-07. PMID:37419676. |
amantadine is an n-methyl-d-aspartate receptor agonist with secondary dopaminergic activity that is used to treat parkinson's disease-related dyskinesia and to treat fatigue in multiple sclerosis. |
2023-07-07 |
2023-08-14 |
Not clear |
| Xuxu Xu, Chaowei Han, Pengcheng Wang, Feimeng Zho. Natural products targeting cellular processes common in Parkinson's disease and multiple sclerosis. Frontiers in neurology. vol 14. 2023-03-27. PMID:36970529. |
the hallmarks of parkinson's disease (pd) include the loss of dopaminergic neurons and formation of lewy bodies, whereas multiple sclerosis (ms) is an autoimmune disorder with damaged myelin sheaths and axonal loss. |
2023-03-27 |
2023-08-14 |
Not clear |
| Md Ashraf-Uz-Zaman, Guangchen Ji, Dalton Tidwell, Linda Yin, Smathorn Thakolwiboon, Jie Pan, Riley Junell, Zach Griffin, Sadisna Shahi, Derek Barthels, Md Sanaullah Sajib, Paul C Trippier, Constantinos M Mikelis, Hiranmoy Das, Mirla Avila, Volker Neugebauer, Nadezhda A Germa. Evaluation of Urea-Based Inhibitors of the Dopamine Transporter Using the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis. ACS chemical neuroscience. 2022-01-03. PMID:34978174. |
for conditions such as parkinson's disease and multiple sclerosis (ms), pharmacological modulation of dopamine (da) system activity is thought to have therapeutic relevance, providing the basis for using dopaminergic agents as a treatment of relevant states. |
2022-01-03 |
2023-08-13 |
Not clear |
| E C D Gonçalves, V Lieberknecht, V V Horewicz, B D Rabelo, F A Felipetti, A L S Rodrigues, D F Martins, R C Dutr. Dopaminergic Receptors as Neuroimmune Mediators in Experimental Autoimmune Encephalomyelitis. Molecular neurobiology. vol 58. issue 11. 2021-11-18. PMID:34432265. |
previous studies have associated imbalances in the dopaminergic system to the pathogenesis of multiple sclerosis (ms). |
2021-11-18 |
2023-08-13 |
mouse |
| Mikhail Melnikov, Anastasiya Sviridova, Vladimir Rogovskii, Vladimir Kudrin, Vladimir Murugin, Alexey Boyko, Mikhail Pashenko. The role of D2-like dopaminergic receptor in dopamine-mediated modulation of Th17-cells in multiple sclerosis. Current neuropharmacology. 2021-08-25. PMID:34429055. |
the role of d2-like dopaminergic receptor in dopamine-mediated modulation of th17-cells in multiple sclerosis. |
2021-08-25 |
2023-08-13 |
human |
| M V Melnikov, A A Sviridova, T V Solodova, A V Lopatina, M V Pashenkov, A N Boyk. [Blockade of D1-like dopaminergic receptors suppresses Th17-cell function in multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 121. issue 7. Vyp. 2. 2021-08-17. PMID:34387452. |
[blockade of d1-like dopaminergic receptors suppresses th17-cell function in multiple sclerosis]. |
2021-08-17 |
2023-08-13 |
Not clear |
| Mikhail Melnikov, Mikhail Pashenkov, Alexey Boyk. Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential? International journal of molecular sciences. vol 22. issue 10. 2021-06-14. PMID:34070011. |
dopaminergic receptor targeting in multiple sclerosis: is there therapeutic potential? |
2021-06-14 |
2023-08-13 |
Not clear |
| Pia M Vidal, Rodrigo Pachec. Targeting the Dopaminergic System in Autoimmunity. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 15. issue 1. 2021-05-27. PMID:30661214. |
in this review we discuss the current evidence involving the dopaminergic system in inflammatory bowel disease, multiple sclerosis and parkinson's disease. |
2021-05-27 |
2023-08-13 |
Not clear |
| Mikhail Melnikov, Vladimir Rogovskii, Alexey Boykо, Mikhail Pashenko. Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 15. issue 1. 2021-05-27. PMID:31011885. |
dopaminergic therapeutics in multiple sclerosis: focus on th17-cell functions. |
2021-05-27 |
2023-08-13 |
Not clear |
| M V Melnikov, M V Pashenkov, A N Boyk. [The prospect of dopaminergic therapy in multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 121. issue 2. 2021-03-18. PMID:33728853. |
recent studies show that by acting on the dopaminergic receptors, it is possible to modulate th17-immune response, which play a crucial role in the pathogenesis of multiple sclerosis. |
2021-03-18 |
2023-08-13 |
Not clear |
| M V Melnikov, M V Pashenkov, A N Boyk. [The prospect of dopaminergic therapy in multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 121. issue 2. 2021-03-18. PMID:33728853. |
in this short communication, the prospects of using dopaminergic therapy as a pathogenetic treatment for multiple sclerosis are discussed. |
2021-03-18 |
2023-08-13 |
Not clear |
| M V Melnikov, M V Pashenkov, A N Boyk. [The prospect of dopaminergic therapy in multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 121. issue 2. 2021-03-18. PMID:33728853. |
dopamine can modulate th17 cells function as well as dendritic cell-mediated th17-immune response that allows considering dopaminergic receptors as a new therapeutic target in multiple sclerosis. |
2021-03-18 |
2023-08-13 |
Not clear |
| M V Melnikov, M V Pashenkov, A N Boyk. [The prospect of dopaminergic therapy in multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 121. issue 2. 2021-03-18. PMID:33728853. |
[the prospect of dopaminergic therapy in multiple sclerosis]. |
2021-03-18 |
2023-08-13 |
Not clear |
| Marco Cosentino, Mauro Zaffaroni, Massimiliano Legnaro, Raffaella Bombelli, Laura Schembri, Damiano Baroncini, Anna Bianchi, Raffaella Clerici, Mario Guidotti, Paola Banfi, Giorgio Bono, Franca Marin. Dataset of mRNA levels for dopaminergic receptors, adrenoceptors and tyrosine hydroxylase in lymphocytes from subjects with clinically isolated syndromes. Data in brief. vol 9. 2020-10-01. PMID:27699190. |
this data article presents a dataset of mrna levels for dopaminergic receptors, adrenoceptors and for tyrosine hydoxylase, the rate-limiting enzyme in the synthesis of catecholamines, in peripheral blood mononuclear cells as well as in cd4+ t effector and regulatory cells from subjects with clinically isolated syndromes (cis), which is a first episode of neurological disturbance(s) suggestive of multiple sclerosis. |
2020-10-01 |
2023-08-13 |
human |
| Marco Cosentino, Mauro Zaffaroni, Massimiliano Legnaro, Raffaella Bombelli, Laura Schembri, Damiano Baroncini, Anna Bianchi, Raffaella Clerici, Mario Guidotti, Paola Banfi, Giorgio Bono, Franca Marin. Dataset of mRNA levels for dopaminergic receptors, adrenoceptors and tyrosine hydroxylase in lymphocytes from subjects with clinically isolated syndromes. Data in brief. vol 9. 2020-10-01. PMID:27699190. |
the data reported are related to the article entitled "dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis" (m. cosentino, m. zaffaroni, m. legnaro, r. bombelli, l. schembri, d. baroncini, a. bianchi, r. clerici, m. guidotti, p. banfi, g. bono, f. marino, 2016) [1]. |
2020-10-01 |
2023-08-13 |
human |
| Mario Habe. Immune and autonomic nervous system interactions in multiple sclerosis: clinical implications. Clinical autonomic research : official journal of the Clinical Autonomic Research Society. vol 29. issue 3. 2020-07-03. PMID:30963343. |
changes in the sympathetic autonomic system, such as different expression of dopaminergic and adrenergic receptors on immune cells, or modulation of the cholinergic anti-inflammatory pathway over different subunits of the nicotinic acetylcholine receptor in the peripheral immune system, may mediate different effects on multiple sclerosis disease activity. |
2020-07-03 |
2023-08-13 |
Not clear |
| Valtteri Kaasinen, Juho Joutsa, Eero Rissanen, Laura Airas, Merja Soilu-Hänninen, Tommi Nopone. Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis. Multiple sclerosis and related disorders. vol 36. 2020-05-19. PMID:31518774. |
dopamine has a modulatory role in a number of autoimmune diseases, but there are no published cases of longitudinal dopaminergic imaging in multiple sclerosis (ms). |
2020-05-19 |
2023-08-13 |
Not clear |
| Valtteri Kaasinen, Juho Joutsa, Eero Rissanen, Laura Airas, Merja Soilu-Hänninen, Tommi Nopone. Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis. Multiple sclerosis and related disorders. vol 36. 2020-05-19. PMID:31518774. |
progressive dopaminergic defect in a patient with primary progressive multiple sclerosis. |
2020-05-19 |
2023-08-13 |
Not clear |
| Shima Tavakol, Elham Hoveizi, Behnaz Tavakol, Fereshteh Azedi, Somayeh Ebrahimi-Barough, Peyman Keyhanvar, Mohammad Taghi Joghatae. Small molecule of sphingosine as a rescue of dopaminergic cells: A cell therapy approach in neurodegenerative diseases therapeutics. Journal of cellular physiology. vol 234. issue 7. 2020-05-12. PMID:30623407. |
multiple sclerosis (ms) patients should take medication such as fingolimod (fty-720) for a long time, hence pharmaceutical effects on other neural cells such as dopaminergic cells are important. |
2020-05-12 |
2023-08-13 |
Not clear |